APx Acquisition Corp IAPXI
APXI
About: APx Acquisition Corp I is a newly incorporated blank check company.
Employees: 2
0
Funds holding %
of 6,790 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
22.66% more ownership
Funds ownership: 52.05% [Q2] → 74.71% (+22.66%) [Q3]
5% more capital invested
Capital invested by funds: $59.8M [Q2] → $62.6M (+$2.77M) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
14% less funds holding
Funds holding: 22 [Q2] → 19 (-3) [Q3]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Research analyst outlook
We haven’t received any recent analyst ratings for APXI.
Financial journalist opinion
Neutral
PRNewsWire
1 month ago
APX Acquisition Corp. I Announces Nasdaq Delisting Notification for Warrants and Units
NASHVILLE, Tenn. , Nov. 1, 2024 /PRNewswire/ -- As previously announced, on September 4, 2024, APX Acquisition Corp. I (NASDAQ: APXI ) (the "Company"), received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") indicating that since the Company's aggregate market value of its outstanding warrants was less than $1 million, the Company was no longer in compliance with the Nasdaq Global Market continued listing criteria set forth in Listing Rule 5452(b)(C) (the "Rule"), which requires the Company to maintain an aggregate market value of its outstanding warrants of at least $1 million (the "Notice").
Neutral
PRNewsWire
6 months ago
APX Acquisition Corp. I Reports 10-K Delinquency Notice
NASHVILLE, Tenn. , June 5, 2024 /PRNewswire/ -- APX Acquisition Corp. I (NASDAQ: APXI ) ("Company"), a publicly traded special purpose acquisition company, today announced that it received a deficiency letter (the "Letter") on May 30, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq").
Neutral
PRNewsWire
8 months ago
APx Acquisition Corp. I, OmnigenicsAI Corp and MultiplAI Health Ltd enter into Business Combination Agreement to create a global AI-driven genomics platform
NASHVILLE, Tenn. , March 26, 2024 /PRNewswire/ -- APx Acquisition Corp. I (NASDAQ: APXI) ("APx"), a publicly traded special purpose acquisition company, OmnigenicsAI Corp ("OmnigenicsAI"), a precision medicine company incubated by Bioceres Group PLC, and MultiplAI Health Ltd ("MultiplAI"), a UK-based AI-enabled preventive medicine company, have entered into a definitive Business Combination Agreement ("BCA") that, upon closing, would result in OmnigenicsAI becoming a publicly listed company.
Neutral
PRNewsWire
11 months ago
APX Acquisition Corp. I receives Nasdaq notice on late filing of its Form 10-Q
NASHVILLE, Tenn., Dec. 28, 2023 /PRNewswire/ -- APX Acquisition Corp. I (NASDAQ: APXI) ("Company"), a publicly traded special purpose acquisition company, today announced that it received a deficiency letter (the "Letter") on December 21, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq").
Neutral
PRNewsWire
1 year ago
APX Acquisition Corp. I & Bioceres Group Announce Letter of Intent for a Business Combination with a Precision Medicine Diagnostic and Wellness Services Company
NASHVILLE, Tenn. , Dec. 1, 2023 /PRNewswire/ -- APX Acquisition Corp. I (NASDAQ: APXI) ("Company"), a publicly traded special purpose acquisition company, announced today that it has signed a non-binding letter of intent ("LOI") for a proposed business combination (the "Business Combination") with a precision medicine company that offers genomic diagnostic tests in clinical genomics, oncology, human microbiome and reproductive genomics, as well as a digital nutrition-based DNA and gut microbiome wellness service that promotes wellbeing and prevents disease ("Target"), that would result in a public listing of the combined company upon completion of the proposed Business Combination.
Charts implemented using Lightweight Charts™